Skip to main content
LIMN
NASDAQ Life Sciences

CEO-Controlled Entity Disposes of 8.5% of Liminatus Pharma Shares Without Consideration

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.14
Mkt Cap
$7.217M
52W Low
$0.095
52W High
$10.198
52W Position info
48% above low
Off High info
99% below high
Rel. Volume info
2.7× avg
Market data snapshot near publication time

LIMN sits 48% above its 52-week low of $0.095 on elevated volume (2.7× avg).

Summary

Valetudo Therapeutics, an entity controlled by CEO Chris Kim, disposed of 4.37 million shares of Liminatus Pharma, representing 8.5% of the company, to Ewon Comfortech Co., Ltd. The transfer involved no cash consideration, and Valetudo retains voting power.


Key Events · Ownership and Investor Activity · LIMN

  • Significant Share Disposition by CEO-Controlled Entity

    Valetudo Therapeutics LLC, controlled by CEO Chris Kim, disposed of 4,373,603 shares of common stock, representing 8.5% of the company's market capitalization.

  • Transfer Without Cash Consideration

    The shares were transferred to Ewon Comfortech Co., Ltd. without any payment of consideration, though Valetudo Therapeutics retains voting power over these shares.

  • Context of Recent Corporate Activity

    This disposition occurred on June 24, 2026, the same day an S-1 registration for resale by Armistice Capital was filed, and amidst the company's recent acquisition of InnocsAI and ongoing financial and delisting challenges.


Analysis · LIMN · Life Sciences

Valetudo Therapeutics LLC, an entity controlled by CEO Chris Kim, transferred a substantial block of 4.37 million shares, representing 8.5% of the company's market capitalization, to Ewon Comfortech Co., Ltd. While the transaction involved no cash consideration and Valetudo retains voting power, this still marks a significant shift in direct ownership for a key insider. This disposition occurred on the same day an S-1 registration for resale by another investor was filed, and amidst the company's ongoing financial challenges, including a going concern warning, a recent Nasdaq delisting notice, and the completion of a major acquisition.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LIMN was trading at $0.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.10 to $10.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LIMN - Latest Insights

LIMN
Aug 18, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.1083
Real-time Price: $2.92 info
Change: Reverse Stock Split info
Market Cap: $3.949M info
LIMN
Aug 18, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1161
Real-time Price: $2.92 info
Change: Reverse Stock Split info
Market Cap: $3.949M info
LIMN
Aug 14, 2026, 4:51 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1313
Real-time Price: $2.92 info
Change: Reverse Stock Split info
Market Cap: $3.949M info
LIMN
Jul 29, 2026, 9:49 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.107
Real-time Price: $2.92 info
Change: Reverse Stock Split info
Market Cap: $3.949M info
LIMN
Jul 24, 2026, 4:51 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.1086
Real-time Price: $2.92 info
Change: Reverse Stock Split info
Market Cap: $3.949M info